TAVR safe and effective for patients presenting with mitral annular calcium

Michael Walter | July 28, 2022 | Cardiovascular Business | TAVR

Mitral annular calcium (MAC) does not appear to have a negative effect on long-term transcatheter aortic valve replacement (TAVR) outcomes, according to new research published in the American Journal of Cardiology. Image courtesy of Lak et al. and the Cleveland Clinic.

“MAC is a chronic degenerative process, which is increasing in prevalence in an aging population,” wrote first author Hassan Mehmood Lak, MD, a cardiologist with Cleveland Clinic’s Sydell and Arnold Miller Family Heart Vascular and Thoracic Institute, and colleagues. “It is considered a marker of advanced cardiovascular disease and is an independent risk factor of cardiovascular mortality. However, there are limited data available regarding the impact of concomitant MAC on the outcomes of TAVR, because these patients were traditionally excluded from various pivotal TAVR trials.”

Lak et al. tracked retrospective data from 468 patients who underwent TAVR at the same high-volume facility in 2018. Fifty-eight percent of patients presented with MAC, which was determined using cardiac CT imaging. Patients in the MAC group had an older median age (81 years old vs. 79 years old) and higher body mass index (29.30 vs. 28.05). Patients younger than 18 years old were excluded altogether from the analysis.

Overall, there was no significant difference in all-cause one- or two-year mortality between patients with and without MAC. The myocardial infarction, stroke and major adverse cardiac and cerebrovascular event rates after one year were also comparable between these two groups.

MAC patients did present with higher new-onset left bundle branch block (LBBB) rates, the authors added, but no such differences were seen in complete atrioventricular block or pacemaker implantation rates.

“TAVR is a safe alternative for patients with severe aortic stenosis and concomitant MAC, with comparable outcomes to patients without MAC irrespective of its severity,” the authors concluded, adding that “larger prospective studies” are still required to confirm these findings.

Using a TAVR-like minimalist approach for valve-in-valve TMVR is safe and effective, Cleveland Clinic study confirms

Subclinical leaflet thrombosis after TAVR: What we know, and still need to learn, about a challenging complication

TAVR outcomes take a hit when patients present with heart failure or hypertrophic cardiomyopathy

VIDEO: The state of TAVR in 2022

Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business

U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.